GlassScriptPhysician profile
Alexander Kirifides
NPI 1184642134
$1,888.06
in general payments reported to CMS, 2019-2025
26 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $113 · 2021: $281 · 2022: $483 · 2023: $346 · 2024: $240 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.78 |
| Education | $155.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $527.90 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $243.69 | 2021-2025 | |
| Coopersurgical, INC. | $175.28 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $165.86 | 2019-2025 | |
| Amgen INC. | $129.86 | 2019-2025 | Evenity |
| Sage Therapeutics, LLC | $83.74 | 2022-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $53.01 | 2021 | |
| Exeltis, USA INC. | $48.64 | 2022-2025 | Slynd |
| Allergan, INC. | $48.17 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $41.07 | 2021-2022 | |
| Medtronic, INC. | $39.99 | 2021 | |
| Pfizer INC. | $38.56 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $36.46 | 2021-2023 | |
| Covidien LP | $34.05 | 2020 | |
| Millicent US INC | $29.34 | 2019-2024 | Intrarosa, Femring |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $27.38 | 2022 | |
| Lupin INC. | $25.45 | 2019 | |
| Radius Health, INC. | $22.92 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.47 | 2023 | Flumist Quadrivalent |
| Abbott Laboratories | $19.33 | 2022 | |
| Therapeuticsmd, INC. | $18.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.07 | 2021 | |
| Avion Pharmaceuticals | $14.91 | 2022 | |
| Daiichi Sankyo INC. | $14.87 | 2023 | Injectafer |
| Organon LLC | $14.65 | 2025 | Nexplanon |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kirifides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.